Author: admin

DelveInsight’s “Common Warts Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Common Warts, historical and forecasted epidemiology as well as the Common Warts market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Common Warts market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Common Warts Market Forecast

Some of the key facts of the Common Warts Market Report:

• The Common Warts market size was valued approximately USD 700 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In January 2026, Verrica Pharmaceuticals Inc. recently announced the launch of a global Phase III clinical development program to evaluate VP-102 for the treatment of common warts, with the first patient dosed in December 2025. This milestone marks an expansion of VP-102’s clinical development beyond its approved use in molluscum contagiosum and underscores the company’s continued commitment to addressing unmet needs in dermatology.

• In July 2025, Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology-focused therapeutics company specializing in treatments for skin conditions requiring medical intervention, announced it has signed a second amendment to its Collaboration and Licensing Agreement with Torii Pharmaceutical Co. Ltd. (“Torii”). This amendment supports the launch of a global pivotal Phase 3 clinical trial for Verrica’s product, YCANTH®, aimed at treating common warts.

• In February 2025, Nielsen BioSciences, Inc., a privately held biopharmaceutical company based in San Diego, announced the successful enrollment of the final participant in CFW-3A—a Phase 3, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of CANDIN® (Candida albicans Skin Test Antigen for Cellular Hypersensitivity) for treating common warts (Verruca vulgaris) in both adolescents and adults. CANDIN is not yet approved for this indication.

• In December 2024, Veradermics was a late-stage clinical biopharmaceutical company specializing in aesthetics and dermatology, focused on developing innovative treatments for prevalent skin conditions. Its lead candidate, VDPHL01, is a non-hormonal oral therapy currently under evaluation for androgenetic alopecia (AGA) and pattern hair loss (PHL) in both men and women. The company’s pipeline also includes treatments for common dermatologic conditions such as warts and molluscum contagiosum.

• The US represents the largest market for common warts, comprising about 50% of the total market size across the 7MM. In contrast, Japan generated the least revenue due to its smaller patient population.

• Several therapies poised for approval, such as VP-102 from Verrica Pharmaceuticals and CANDIN from Nielsen BioSciences and Maruho, could significantly impact and potentially expand the market for common warts.

• In May 2024, Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a company focused on dermatological treatments for skin conditions, has announced a revision to its licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii). The updated agreement involves collaborating on a global pivotal Phase 3 clinical trial for YCANTH®, aimed at treating common warts.

• In May 2024, XOLREMDI™ (mavorixafor) is a groundbreaking, once-daily oral medication used to treat WHIM syndrome, a rare immunodeficiency disorder characterized by warts, hypogammaglobulinemia, infections, and myelokathexis, in patients aged 12 and older. Developed by X4 Pharmaceuticals, a US-based biopharmaceutical firm, XOLREMDI™ functions as a selective CXC chemokine receptor 4 (CXCR4) antagonist.

• In 2023, the 7MM reported approximately 14 million diagnosed prevalent cases of common warts. This number is projected to grow substantially by 2034, driven by increased disease awareness and advancements in diagnosis.

• In 2023, the US reported the highest number of diagnosed prevalent cases of common warts among the 7MM, representing nearly 20% of the total cases.

• In the EU4 and the UK, Germany had the highest share of cases, making up nearly 25% of the total cases in the region, followed by France, the UK, Italy, and Spain.

• According to DelveInsight analysis, Japan had the lowest number of diagnosed prevalent cases of common warts among the 7MM countries, with approximately 1.3 million cases in 2023.

• Key Common Warts Companies: Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others

• Key Common Warts Therapies: CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others

• The Common Warts epidemiology based on gender analyzed that the diagnosed prevalent cases were observed to be same for male and female in the 7MM

• The Common Warts market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Common Warts pipeline products will significantly revolutionize the Common Warts market dynamics.

Common Warts Overview

Common warts are benign growths on the skin caused by an infection with human papillomavirus (HPV). They are typically rough, raised, and have a grainy appearance. Common warts are most frequently found on the hands, fingers, and around the nails, but they can appear on other areas of the body as well.

Get a Free sample for the Common Warts Market Report:

https://www.delveinsight.com/report-store/common-warts-market

Common Warts Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Common Warts Epidemiology Segmentation:

The Common Warts market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Common Warts

• Prevalent Cases of Common Warts by severity

• Gender-specific Prevalence of Common Warts

• Diagnosed Cases of Episodic and Chronic Common Warts

Download the report to understand which factors are driving Common Warts epidemiology trends @ Common Warts Epidemiology Forecast

Common Warts Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Common Warts market or expected to get launched during the study period. The analysis covers Common Warts market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Common Warts Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Common Warts Therapies and Key Companies

• CANDIN: Nielsen BioSciences/Maruho

• VP-102: Verrica Pharmaceutical

• FIT039: Kino Pharma/ Iwaki Pharmaceutical

• A-101: Aclaris Therapeutics, Inc.

• KNP2002: KinoPharma Inc.

• 10% EISO: ViroXis Corporation

• CLS006: Maruho Co., Ltd.

• VDMN-21: Veradermics, Inc.

• Resiquimod: Graceway Pharmaceuticals, LLC

• Imiquimod: MEDA Pharma

• Picato: LEO Pharma

Discover more about therapies set to grab major Common Warts market share @ Common Warts Treatment Market

Common Warts Market Strengths

• The rising prevalence of warts is encourages companies in the life sciences industry to focus on research and development of new drugs for warts treatment. There is a continuous need for new, innovative therapeutic approaches for better treatment outcomes.

• An increase in emerging new drugs for the treatment of warts will lead to better patient outcomes in the coming years.

Common Warts Market Opportunities

• Recent studies have shown the safe and efficacious role of Zinc supplementation in warts clearance, particularly for patients who have not responded to treatments previously.

• Secondary research on the warts therapeutics market suggests that the market is saturated with limited drug opportunities providing the key Pharma players a successful domain to work with utmost robustness

Scope of the Common Warts Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Common Warts Companies: Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others

• Key Common Warts Therapies: CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others

• Common Warts Therapeutic Assessment: Common Warts current marketed and Common Warts emerging therapies

• Common Warts Market Dynamics: Common Warts market drivers and Common Warts market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Common Warts Unmet Needs, KOL’s views, Analyst’s views, Common Warts Market Access and Reimbursement

To know more about Common Warts companies working in the treatment market, visit @ Common Warts Clinical Trials and Therapeutic Assessment

Table of Contents

1. Common Warts Market Report Introduction

2. Executive Summary for Common Warts

3. SWOT analysis of Common Warts

4. Common Warts Patient Share (%) Overview at a Glance

5. Common Warts Market Overview at a Glance

6. Common Warts Disease Background and Overview

7. Common Warts Epidemiology and Patient Population

8. Country-Specific Patient Population of Common Warts

9. Common Warts Current Treatment and Medical Practices

10. Common Warts Unmet Needs

11. Common Warts Emerging Therapies

12. Common Warts Market Outlook

13. Country-Wise Common Warts Market Analysis (2020–2034)

14. Common Warts Market Access and Reimbursement of Therapies

15. Common Warts Market Drivers

16. Common Warts Market Barriers

17. Common Warts Appendix

18. Common Warts Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Common Warts Market: Expanding Revenue Landscape to 2034 – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics

The Stargardt Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stargardt Disease pipeline products will significantly revolutionize the Stargardt Disease market dynamics.

DelveInsight’s “Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Stargardt Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Stargardt Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Stargardt Disease Market Insights

Some of the key facts of the Stargardt Disease Market Report:

• The Stargardt Disease market size was valued ~USD 27 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In January 2026, Ocugen, Inc. reported encouraging outcomes from its Phase 1 GARDian1 study of OCU410ST, an innovative gene therapy being developed for Stargardt disease, published in Nature Eye. The study showed a favorable safety and tolerability profile, along with meaningful clinical benefits over a 12-month period. Notably, treated patients experienced a 54% reduction in atrophic lesion progression and improvements in visual acuity. Unlike mutation-specific approaches, OCU410ST is designed to alter the underlying disease course, positioning it as a potentially transformative option for the more than 100,000 individuals affected across the U.S. and Europe, where no approved therapies currently exist. Meanwhile, the Phase 2/3 GARDian3 trial is progressing ahead of plan, with a Biologics License Application (BLA) submission targeted for 2027.

• In December 2025, A Phase 3 study evaluating Belite Bio’s tinlarebant in adolescents with a rare inherited eye disorder has achieved its primary endpoint, prompting the company to include the U.S. among the countries where it plans to seek approval next year. The trial enrolled 104 participants with Stargardt disease type 1 (STGD1), who were assigned to either tinlarebant or placebo. STGD1 leads to lesion formation in the retina and progressive central vision loss. Tinlarebant, an oral therapy, aims to limit the buildup of vitamin A–derived toxins that fuel the disease. The treatment produced a 35.7% reduction in lesion growth compared to placebo. A post hoc analysis accounting for disease progression showed similar outcomes, as did additional lesion-growth metrics.

• In September 2025, VeonGen Therapeutics was granted FDA RMAT designation for VG801, a gene therapy designed to treat Stargardt disease and other ABCA4-related retinal disorders. VG801 employs a dual AAV vector along with the company’s vgRNA REVeRT platform to deliver a functional ABCA4 gene using an engineered vgAAV capsid targeted to photoreceptor cells.

• In August 2025, AAVantgarde Bio was granted FDA Fast Track Designation for AAVB-039, its advanced gene therapy targeting Stargardt disease caused by biallelic ABCA4 mutations. Additionally, the FDA has approved the IND application for AAVB-039, allowing the therapy to progress into clinical development.

• In June 2025, Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company at the forefront of gene therapies for vision-related diseases, has announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) amendment to launch a Phase 2/3 pivotal confirmatory trial of OCU410ST. This modifier gene therapy candidate is being developed to treat all forms of Stargardt disease (ABCA4-associated retinopathies). OCU410ST has already received both Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA for the treatment of ABCA4-related conditions, including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

• In March 2025, Barcelona-based genetic medicines company, SpliceBio, has administered the first dose in the Phase 1/2 ASTRA clinical trial (NCT identifier pending) evaluating SB-007, a dual adeno-associated virus (AAV) vector-based gene therapy for Stargardt disease. This inherited retinal disorder, caused by mutations in the ABCA4 gene, leads to progressive vision loss and currently has no approved treatments. Affecting approximately 1 in 8,000 to 10,000 people, it is the most common form of inherited juvenile macular degeneration.

• In February 2025, Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company specializing in gene therapies for blindness diseases, has secured alignment with the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2/3 pivotal confirmatory trial for OCU410ST. If the trial yields positive results, it could serve as the foundation for a biologics license application (BLA) submission.

• In January 2025, Alkeus Pharmaceuticals, Inc., a biopharmaceutical company focused on retinal disease treatment, has reported positive interim results from its TEASE-3 study. The data indicate that early-stage Stargardt disease patients receiving oral gildeuretinol acetate exhibited no disease progression and maintained stable visual acuity over multiple years.

• In September 2024, Nanoscope Therapeutics Inc., a clinical-stage biotechnology firm focused on gene therapies for retinal degenerative diseases and age-related macular degeneration (AMD), announced a successful End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). The meeting focused on the clinical program assessing MCO-010 for treating severe vision loss caused by Stargardt Macular Degeneration (SMD), paving the way for the progression of MCO-010 to a Phase 3 registrational trial.

• According to DelveInsight’s estimates, the United States held the largest share of the Stargardt Disease treatment market in 2023, representing nearly 55% of the total market value, surpassing the combined market share of the EU4, the UK, and Japan.

• By 2034, MCO-010 (Sonpiretigene Isteparvovec) is projected to hold the largest market share across the 7MM, with ALK-001 (gildeuretinol) expected to follow as the second-leading therapy.

• During the 2024–2034 forecast period, the Stargardt Disease market size is projected to grow significantly, driven by emerging pipeline therapies such as ALK-001 (gildeuretinol), Tinlarebant (LSB-008), IZERVAY (avacincaptad pegol), Emixustat, along with gene therapy candidates like MCO-010 (Sonpiretigene Isteparvovec) and others. These advancing treatments are expected to play a key role in market expansion.

• Stargardt disease, also called Stargardt’s macular dystrophy or juvenile macular degeneration, is a rare inherited eye disorder caused by the accumulation of fatty deposits on the macula—the central part of the retina responsible for detailed vision. It is the most common form of recessive macular dystrophy in children and is estimated to affect about 10 to 12.5 individuals per 100,000 in the United States.

• Across the 7MM regions, the United States recorded the largest share of diagnosed prevalent cases of Stargardt Disease in 2023, representing 43% of all diagnosed incidents.

• In the US, the greatest number of age-specific onset cases in 2020 occurred in individuals aged over 20 years, followed by those between 20 and 39 years. In comparison, the lowest number of cases was reported in people aged 60 years and above.

• Key Stargardt Disease Companies: Ocugen, Kubota Vision Inc, Nanoscope Therapeutics Inc., RBP4 Pty Ltd, Stargazer Pharmaceuticals, Inc., Belite Bio, Inc, Alkeus Pharmaceuticals, Inc., IVERIC bio, Inc., Kubota Vision Inc., Astellas Institute, Nanoscope Therapeutics, Alkeus Pharmaceuticals, and others

• Key Stargardt Disease Therapies: OCU410ST, Emixustat, Gene Therapy-vMCO-010, tinlarebant, STG-001, Tinlarebant, ALK-001, Zimura, Emixustat, MA09-hRPE, MCO-010 (Sonpiretigene Isteparvovec), ALK-001 (Gildeuretinol), and others

• The Stargardt Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stargardt Disease pipeline products will significantly revolutionize the Stargardt Disease market dynamics.

Stargardt Disease Overview

Stargardt disease is a rare inherited eye disorder that causes progressive vision loss, primarily affecting the macula the part of the retina responsible for sharp, central vision. It is most commonly caused by mutations in the ABCA4 gene, leading to the buildup of toxic fatty deposits in retinal cells. Symptoms typically begin in childhood or adolescence and may include blurred vision, difficulty seeing in low light, and loss of color perception. Over time, the condition can lead to significant central vision impairment, though peripheral vision is usually preserved. There is currently no cure, but several emerging therapies and gene treatments are under development.

Get a Free sample for the Stargardt Disease Market Report:

https://www.delveinsight.com/report-store/stargardt-disease-stgd-market

Stargardt Disease Market

The dynamics of the Stargardt Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

“In the near future, there are some positive candidates in the developmental stage by key players such as Acucela Inc (Kubota), Alkeus Pharmaceuticals Inc, Astellas Pharma Inc, Revision Therapeutics and others.”

Stargardt Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Stargardt Disease Epidemiology Segmentation:

The Stargardt Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Stargardt Disease

• Prevalent Cases of Stargardt Disease by severity

• Gender-specific Prevalence of Stargardt Disease

• Diagnosed Cases of Episodic and Chronic Stargardt Disease

Download the report to understand which factors are driving Stargardt Disease epidemiology trends @ Stargardt Disease Epidemiological Insights

Stargardt Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Stargardt Disease market or expected to get launched during the study period. The analysis covers Stargardt Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Stargardt Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Stargardt Disease Therapies and Key Companies

• OCU410ST: Ocugen

• Emixustat: Kubota Vision Inc

• Gene Therapy-vMCO-010: Nanoscope Therapeutics Inc.

• tinlarebant: RBP4 Pty Ltd

• STG-001: Stargazer Pharmaceuticals, Inc.

• Tinlarebant: Belite Bio, Inc

• ALK-001: Alkeus Pharmaceuticals, Inc.

• Zimura: IVERIC bio, Inc.

• Emixustat: Kubota Vision Inc.

• MA09-hRPE: Astellas Institute

• Emixustat : Kubota Pharmaceuticals

• MCO-010 (Sonpiretigene Isteparvovec): Nanoscope Therapeutics

• ALK-001 (Gildeuretinol): Alkeus Pharmaceuticals

To know more about Stargardt Disease treatment, visit @ Stargardt Disease Medications

Stargardt Disease Market Strengths

• Stargardt Disease has a well-identified genetic basis, primarily associated with mutations in the ABCA4 gene, allowing for targeted research and potential therapeutic interventions.

• Regulatory agencies, such as the FDA, recognize Stargardt Disease as an orphan disease, providing incentives for the development of orphan drugs and accelerated approval pathways.

Stargardt Disease Market Opportunities

• Ongoing research in gene therapies, pharmacological interventions, and emerging technologies provides opportunities for the development of novel and effective treatments.

• Rapid advancements in genetic technologies, including CRISPR-Cas9, offer potential breakthroughs in gene editing and correction of ABCA4 mutations

Scope of the Stargardt Disease Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Stargardt Disease Companies: Ocugen, Kubota Vision Inc, Nanoscope Therapeutics Inc., RBP4 Pty Ltd, Stargazer Pharmaceuticals, Inc., Belite Bio, Inc, Alkeus Pharmaceuticals, Inc., IVERIC bio, Inc., Kubota Vision Inc., Astellas Institute, Nanoscope Therapeutics, Alkeus Pharmaceuticals, and others

• Key Stargardt Disease Therapies: OCU410ST, Emixustat, Gene Therapy-vMCO-010, tinlarebant, STG-001, Tinlarebant, ALK-001, Zimura, Emixustat, MA09-hRPE, MCO-010 (Sonpiretigene Isteparvovec), ALK-001 (Gildeuretinol), Zimura, and others

• Stargardt Disease Therapeutic Assessment: Stargardt Disease current marketed and Stargardt Disease emerging therapies

• Stargardt Disease Market Dynamics: Stargardt Disease market drivers and Stargardt Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Stargardt Disease Unmet Needs, KOL’s views, Analyst’s views, Stargardt Disease Market Access and Reimbursement

Discover more about therapies set to grab major Stargardt Disease market share @ Stargardt Disease Treatment Landscape

Table of Contents

1. Stargardt Disease Market Report Introduction

2. Executive Summary for Stargardt Disease

3. SWOT analysis of Stargardt Disease

4. Stargardt Disease Patient Share (%) Overview at a Glance

5. Stargardt Disease Market Overview at a Glance

6. Stargardt Disease Disease Background and Overview

7. Stargardt Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Stargardt Disease

9. Stargardt Disease Current Treatment and Medical Practices

10. Stargardt Disease Unmet Needs

11. Stargardt Disease Emerging Therapies

12. Stargardt Disease Market Outlook

13. Country-Wise Stargardt Disease Market Analysis (2020–2034)

14. Stargardt Disease Market Access and Reimbursement of Therapies

15. Stargardt Disease Market Drivers

16. Stargardt Disease Market Barriers

17. Stargardt Disease Appendix

18. Stargardt Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharma

“Sarcopenia Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sarcopenia Market.

The Sarcopenia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Sarcopenia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Sarcopenia treatment therapies with a considerable amount of success over the years.

• Sarcopenia companies working in the treatment market are TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others, are developing therapies for the Sarcopenia treatment

• Emerging Sarcopenia therapies in the different phases of clinical trials are- MYMD-1/Isomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510 (ubidecarenone), OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, and others are expected to have a significant impact on the Sarcopenia market in the coming years.

• In September 2025, Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company focused on treatments for neuromuscular and fibrotic diseases, announced positive Phase 1 trial results for MF-300, a novel therapy under development for sarcopenia. The trial met its primary safety endpoint, with all tested doses of MF-300 generally well tolerated and no participant discontinuations. MF-300 showed dose-dependent pharmacodynamic (PD) responses that were evident early and maintained over time, while the placebo group showed no significant changes, confirming target engagement and biological activity. Pharmacokinetic (PK) analysis revealed dose-related increases in exposure, with a half-life supporting convenient once-daily oral dosing.

• In July 2025, Epirium Bio Inc., a clinical-stage biopharmaceutical company focused on neuromuscular and fibrotic diseases, announced the completion of dosing in its Phase 1 trial of MF-300. This randomized, double-blind, placebo-controlled single and multiple ascending dose (SAD/MAD) study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of MF-300 in healthy adults. MF-300, an investigational first-in-class oral inhibitor of the 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme, is being developed to treat sarcopenia, or age-related muscle weakness. Preliminary findings showed all adverse events were mild to moderate, with no severe or serious cases, no early discontinuations, and no stopping criteria met.

• In April 2025, TNF Pharmaceuticals, Inc. announced that Mitchell Glass, M.D., President and Chief Medical Officer of TNF, delivered a platform presentation on the abstract titled “Isomyosamine for the Treatment of Sarcopenia in Older Adults” at the British Geriatrics Society (BGS) Spring Meeting 2025, which took place from April 9–11 in Belfast, Ireland, and online.

Sarcopenia Overview

Muscle mass, strength, and performance are severely hampered with age in sarcopenia, a musculoskeletal condition. Elderly, sedentary individuals as well as people with concomitant conditions that impact the musculoskeletal system or limit physical exercise are most frequently affected by sarcopenia.

Get a Free Sample PDF Report to know more about Sarcopenia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/sarcopenia-pipeline-insight

Emerging Sarcopenia Drugs Under Different Phases of Clinical Development Include:

• MYMD-1/Isomyosamine: TNF Pharmaceuticals

• LPCN 1148: Lipocine

• Sarconeos (BIO101): Biophytis

• Froniglutide (PF-1801): ImmunoForge

• RJx-01: Rejuvenate Biomed

• KER-065: Keros Therapeutics

• BPM 31510 (ubidecarenone): BPGbio

• OC514: Oncocross

• MT29: Mirscience Therapeutics

• TRN-005: Turn Biotechnologies

• NMDP-05: NMD PHARMA

• PF1807: ImmunoForge

• DW1030: Dong Wha PHARM

Sarcopenia Route of Administration

Sarcopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Sarcopenia Molecule Type

Sarcopenia Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Sarcopenia Pipeline Therapeutics Assessment

• Sarcopenia Assessment by Product Type

• Sarcopenia By Stage and Product Type

• Sarcopenia Assessment by Route of Administration

• Sarcopenia By Stage and Route of Administration

• Sarcopenia Assessment by Molecule Type

• Sarcopenia by Stage and Molecule Type

DelveInsight’s Sarcopenia Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Sarcopenia product details are provided in the report. Download the Sarcopenia pipeline report to learn more about the emerging Sarcopenia therapies

Some of the key companies in the Sarcopenia Therapeutics Market include:

Key companies developing therapies for Sarcopenia are – Abbott Nutrition, GSK PLC, Nestle Health Science, Sanofi SA, Bayer AG, Novartis AG, Metagenics LLC, Wellona Pharma, Intas Pharmaceuticals Ltd, Perrigo Company PLC, Dr. Jockers Store, and others.

Sarcopenia Pipeline Analysis:

The Sarcopenia pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Sarcopenia with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sarcopenia Treatment.

• Sarcopenia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Sarcopenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sarcopenia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Sarcopenia drugs and therapies

Sarcopenia Pipeline Market Drivers

• Increase in Prevalence of Sarcopenia, increase in Research and development activities are some of the important factors that are fueling the Sarcopenia Market.

Sarcopenia Pipeline Market Barriers

• However, complications of Sarcopenia treatment, lack of awareness about the disease and other factors are creating obstacles in the Sarcopenia Market growth.

Scope of Sarcopenia Pipeline Drug Insight

• Coverage: Global

• Key Sarcopenia Companies: TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others

• Key Sarcopenia Therapies: MYMD-1/Isomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510 (ubidecarenone), OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, and others

• Sarcopenia Therapeutic Assessment: Sarcopenia current marketed and Sarcopenia emerging therapies

• Sarcopenia Market Dynamics: Sarcopenia market drivers and Sarcopenia market barriers

Request for Sample PDF Report for Sarcopenia Pipeline Assessment and clinical trials

Table of Contents

1. Sarcopenia Report Introduction

2. Sarcopenia Executive Summary

3. Sarcopenia Overview

4. Sarcopenia- Analytical Perspective In-depth Commercial Assessment

5. Sarcopenia Pipeline Therapeutics

6. Sarcopenia Late Stage Products (Phase II/III)

7. Sarcopenia Mid Stage Products (Phase II)

8. Sarcopenia Early Stage Products (Phase I)

9. Sarcopenia Preclinical Stage Products

10. Sarcopenia Therapeutics Assessment

11. Sarcopenia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Sarcopenia Key Companies

14. Sarcopenia Key Products

15. Sarcopenia Unmet Needs

16 . Sarcopenia Market Drivers and Barriers

17. Sarcopenia Future Perspectives and Conclusion

18. Sarcopenia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sarcopenia Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Oncocross, Biophytis, MyMD Pharmaceuticals, Novartis, Regeneron Pharma, Merck